Status: Recruiting
Advanced NanoTherapies Dual-API DCB to Treat De-Novo and ISR Lesions in Patients With Symptomatic Coronary Artery Disease
The study objectives are: 1. To evaluate the safety and performance of the SirPlux Duo PTCA to treat coronary ISR lesions 2.00-4.00 mm (inclusive) in diameter in patients with symptomatic coronary artery disease. 2. To evaluate the safety and performance of the SirPlux Duo PTCA to treat coronary de novo lesions \<3.00 mm in diameter in patients with symptomatic coronary artery disease.
Participants needed: 30
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Advanced NanoTherapiesUpdated: Jan 27, 2026Locations: 3
Eligibility criteria
≥18 years or minimum legal age as required by local regulations. [+11]
Participant is pregnant, or breastfeeding. Note: Participant of childbearing pot... [+26]